In a phase II trial, patients with CRC were administered subcutaneous injection of granulocyte-macrophage colony-stimulating factor and low-dose IL-2 following chemotherapy with gemcitabine plus FOLFOX-4 (oxaliplatin, fluorouracil, and folic acid). The gene discussed is IL2; the disease is colorectal carcinoma.